Education
About Us
Working with TipRanks
Follow Us
InfuSystem Holdings, Inc. (INFU)
:INFU
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -24.66%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
InfuSystem Holdings, Inc. showed strong financial growth with significant increases in revenue, operating income, and adjusted EBITDA. The company also achieved a record operating cash flow and demonstrated potential for future growth with the launch of the Chemo Mouthpiece. However, challenges such as high tax rates and underperformance in the wound care segment were noted, along with the anticipated costs of an ERP upgrade. Overall, the company's highlights outweigh the lowlights, indicating a positive outlook.Company Guidance
In the call, InfuSystem Holdings, Inc. provided guidance for 2025, expecting revenue growth between 8% and 10%, with adjusted EBITDA margins surpassing the 18.8% achieved in 2024. The company anticipates improved adjusted EBITDA despite incurring approximately $2.5 million in expenses related to an ongoing technology systems upgrade. Without these costs, adjusted EBITDA margins could exceed 20%. The company noted that the first-quarter EBITDA margin will be lower, in the mid-teens, due to higher expenses early in the year, followed by significantly higher margins in the latter half of the year. Revenue growth is projected to be driven by new projects and increased adoption of product lines, such as Chemo Mouthpiece and advanced wound care initiatives, along with continued momentum in existing business lines.Strong Financial Performance
Operating income increased 69% to $6.9 million, and adjusted EBITDA increased 13% to $25.3 million with a full-year adjusted EBITDA margin of 18.8%, up from 17.8% in 2023.
Revenue Growth Across Business Lines
Revenues increased by 7.2% year-over-year. Oncology and pain management grew by 6.1% and 14.7%, respectively. Equipment rentals increased by 13.6%, and equipment sales grew by 20.6%.
Record Operating Cash Flow
Operating cash flow reached an all-time annual record of $20.5 million, a 70% increase from the prior year fourth quarter.
Chemo Mouthpiece Launch and Potential
The launch of the Chemo Mouthpiece product, with an addressable market in the hundreds of millions, has generated initial interest and small orders, with potential for broad adoption.
---
INFU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INFU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $7.26 | $6.47 | -10.88% |
| Nov 07, 2024 | $6.98 | $7.34 | +5.16% |
| Aug 08, 2024 | $5.80 | $6.00 | +3.45% |
| May 09, 2024 | $7.94 | $7.56 | -4.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does InfuSystem Holdings, Inc. (INFU) report earnings?
InfuSystem Holdings, Inc. (INFU) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is InfuSystem Holdings, Inc. (INFU) earnings time?
InfuSystem Holdings, Inc. (INFU) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INFU EPS forecast?
INFU EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---